Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL

por Gordon, Caroline, Wofsy, David, Wax, Stephen, Li, Yong, Pena Rossi, Claudia, Isenberg, David
Publicado 2016

Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study

por Pena Rossi, Claudia, Hanauer, Stephen B, Tomasevic, Ratko, Hunter, John O, Shafran, Ira, Graffner, Hans
Publicado 2009

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis

por Emery, Paul, Rondon, Juan, Parrino, Janie, Lin, Yong, Pena-Rossi, Claudia, van Hoogstraten, Hubert, Graham, Neil M H, Liu, Nancy, Paccaly, Anne, Wu, Richard, Spindler, Alberto
Publicado 2019

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension

por Burmester, Gerd R, Strand, Vibeke, Rubbert-Roth, Andrea, Amital, Howard, Raskina, Tatiana, Gómez-Centeno, Antonio, Pena-Rossi, Claudia, Gervitz, Leon, Thangavelu, Karthinathan, St John, Gregory, Boklage, Susan, Genovese, Mark C
Publicado 2019

Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects

por Gillon, Jean‐Yves, Dennison, Jeremy, van den Berg, Frans, Delhomme, Sophie, Dequatre Cheeseman, Karen, Peña Rossi, Claudia, Strub Wourgaft, Nathalie, Specht, Sabine, Pedrique, Belén, Monnot, Frédéric, Skrabs, Susanne, Rodriguez, Maria‐Luisa, Stass, Heino
Publicado 2021